Immunotoxins in the therapy of cancer: From bench to clinic
- 31 December 1994
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 63 (3), 209-234
- https://doi.org/10.1016/0163-7258(94)90025-6
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxinBioconjugate Chemistry, 1994
- Phase I/II Study of Murine Monoclonal Antibody-Ricin A Chain (XOMAZYME-Mel) Immunoconjugate plus Cyclosporine A in Patients with Metastatic MelanomaJournal of Immunotherapy, 1993
- Insertion of constant region domains of human IgG, into CD4-PE40 increases its plasma half-lifeMolecular Immunology, 1993
- Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effectsCancer Immunology, Immunotherapy, 1992
- The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: Evidence that the membrane binding and A-chain translocation activities of ricin cannot be separatedBiochemical and Biophysical Research Communications, 1992
- Thiol-containing crosslinking agent with enhanced steric hindranceBioconjugate Chemistry, 1990
- An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensinInternational Journal of Cancer, 1989
- Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxinJournal of Neurosurgery, 1987
- Studies on components of immunotoxins: Purification of ricin and its subunits and influence of unreacted antibodiesInternational Journal of Cancer, 1985
- Kinetics of divalent monoclonal antibody binding to tumour cell surface antigens using flow cytometry: Standardization and mathematical analysisMolecular Immunology, 1985